EVMN
Evommune, Inc.
NYSE · Healthcare · Biotechnology · US
$12.27
+2.25%Next report
Analyst consensus
- Next report date
- Oct 16, 2026
- EPS estimate
- -$0.82
- Revenue estimate
- $500.0K
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.89
- EPS estimate
- -$0.66
- Revenue actual
- —
- Revenue estimate
- $1.3M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 1
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -236.1%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $28
- PT range
- $26 – $29
- Analysts
- 5
3 Buy2 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 16, 2026